Sanofi (EPA:SAN) has been given a consensus recommendation of “Hold” by the seventeen analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is €87.24 ($101.44).
Several research firms recently commented on SAN. set a €81.00 ($94.19) price objective on Sanofi and gave the company a “neutral” rating in a research report on Wednesday, August 30th. Jefferies Group LLC set a €87.00 ($101.16) price objective on Sanofi and gave the company a “neutral” rating in a research report on Thursday, August 24th. Goldman Sachs Group, Inc. (The) set a €82.00 ($95.35) price objective on Sanofi and gave the company a “neutral” rating in a research report on Monday, August 7th. Deutsche Bank AG set a €96.00 ($111.63) price objective on Sanofi and gave the company a “buy” rating in a research report on Tuesday, August 1st. Finally, J P Morgan Chase & Co set a €90.00 ($104.65) price objective on Sanofi and gave the company a “neutral” rating in a research report on Tuesday, August 1st.
ILLEGAL ACTIVITY WARNING: “Analysts Set Sanofi (SAN) PT at $87.24” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/15/analysts-set-sanofi-san-pt-at-87-24.html.
Shares of Sanofi (EPA:SAN) traded down €0.03 ($0.03) during trading hours on Friday, hitting €75.58 ($87.88). The stock had a trading volume of 2,450,000 shares, compared to its average volume of 1,870,000. Sanofi has a 1 year low of €73.39 ($85.34) and a 1 year high of €92.97 ($108.10).
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.